Patents by Inventor Sabine Münkel

Sabine Münkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • huTNFR1 selective antagonists
    Patent number: 9045535
    Abstract: The present invention relates to a ligand, which specifically binds to human tumor necrosis factor type 1 receptor (huTNFR1). The ligand includes one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in humans and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention also relates to a nucleic acid sequence encoding the ligand and to a pharmaceutical composition for the treatment of disorders related to huTNFR1.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: June 2, 2015
    Assignee: Universitaet Stuttgart
    Inventors: Klaus Pfizenmaier, Peter Scheurich, Roland Kontermann, Sabine Muenkel
  • huTNFR1 SELECTIVE ANTAGONISTS
    Publication number: 20130244341
    Abstract: The present invention relates to a ligand, which specifically binds to human tumor necrosis factor type 1 receptor (huTNFR1). The ligand includes one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in humans and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention also relates to a nucleic acid sequence encoding the ligand and to a pharmaceutical composition for the treatment of disorders related to huTNFR1.
    Type: Application
    Filed: February 13, 2013
    Publication date: September 19, 2013
    Applicant: UNIVERSITAET STUTTGART
    Inventors: Klaus PFIZENMAIER, Peter Scheurich, Roland Kontermann, Sabine Muenkel
  • huTNFR1 selective antagonists
    Patent number: 8404238
    Abstract: The present invention relates to a ligand, which specifically binds to human tumor necrosis factor type 1 receptor (huTNFR1). The ligand includes one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in humans and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention also relates to a nucleic acid sequence encoding the ligand and to a pharmaceutical composition for the treatment of disorders related to huTNFR1.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: March 26, 2013
    Assignee: Universitaet Stuttgart
    Inventors: Klaus Pfizenmaier, Peter Scheurich, Roland Kontermann, Sabine Münkel
  • huTNFR1 Selective Antagonists
    Publication number: 20100150916
    Abstract: The present invention relates to a ligand which specifically binds to the human tumor necrosis factor type 1 receptor (huTNFR1), the ligand comprising one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in human beings and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention further relates to a nucleic acid encoding said ligand and to a pharmaceutical composition for the treatment of disorders connected to huTNFR1.
    Type: Application
    Filed: March 13, 2008
    Publication date: June 17, 2010
    Applicant: UNIVERSITÄT STUTTGART
    Inventors: Klaus Pfizenmaier, Peter Scheurich, Roland Kontermann, Sabine Münkel